Immunovant, Inc. (IMVT)
Total Valuation
Immunovant has a market cap or net worth of $4.65 billion. The enterprise value is $3.96 billion.
Market Cap | 4.65B |
Enterprise Value | 3.96B |
Important Dates
The next estimated earnings date is Monday, May 20, 2024, before market open.
Earnings Date | May 20, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
Immunovant has 145.29 million shares outstanding. The number of shares has increased by 12.40% in one year.
Shares Outstanding | 145.29M |
Shares Change (YoY) | +12.40% |
Shares Change (QoQ) | +10.19% |
Owned by Insiders (%) | 55.50% |
Owned by Institutions (%) | 47.64% |
Float | 64.47M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | n/a |
PB Ratio | 6.84 |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 22.14, with a Debt / Equity ratio of 0.00.
Current Ratio | 22.14 |
Quick Ratio | 21.56 |
Debt / Equity | 0.00 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -61.10% and return on invested capital (ROIC) is -39.15%.
Return on Equity (ROE) | -61.10% |
Return on Assets (ROA) | -55.30% |
Return on Capital (ROIC) | -39.15% |
Revenue Per Employee | n/a |
Profits Per Employee | -$1.48M |
Employee Count | 164 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | -656,000 |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +107.80% in the last 52 weeks. The beta is 0.72, so Immunovant's price volatility has been lower than the market average.
Beta (1Y) | 0.72 |
52-Week Price Change | +107.80% |
50-Day Moving Average | 35.47 |
200-Day Moving Average | 31.08 |
Relative Strength Index (RSI) | 45.94 |
Average Volume (30 Days) | 1,268,445 |
Short Selling Information
The latest short interest is 9.35 million, so 6.44% of the outstanding shares have been sold short.
Short Interest | 9.35M |
Short Previous Month | 8.68M |
Short % of Shares Out | 6.44% |
Short % of Float | 14.51% |
Short Ratio (days to cover) | 7.93 |
Income Statement
Revenue | n/a |
Gross Profit | n/a |
Operating Income | -266.09M |
Pretax Income | -244.11M |
Net Income | -243.45M |
EBITDA | -242.72M |
EBIT | -244.11M |
Earnings Per Share (EPS) | -$1.83 |
Balance Sheet
The company has $690.94 million in cash and $306,000 in debt, giving a net cash position of $690.63 million or $4.75 per share.
Cash & Cash Equivalents | 690.94M |
Total Debt | 306,000 |
Net Cash | 690.63M |
Net Cash Per Share | $4.75 |
Equity / Book Value | 679.34M |
Book Value Per Share | 4.68 |
Working Capital | 678.67M |
Cash Flow
In the last 12 months, operating cash flow was -$210.32 million and capital expenditures -$236,000, giving a free cash flow of -$210.56 million.
Operating Cash Flow | -210.32M |
Capital Expenditures | -236,000 |
Free Cash Flow | -210.56M |
FCF Per Share | -$1.46 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
Immunovant does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -12.40% |
Shareholder Yield | -12.40% |
Earnings Yield | -5.24% |
FCF Yield | -4.53% |
Analyst Forecast
The average price target for Immunovant is $44.67, which is 38.25% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $44.67 |
Price Target Difference | 38.25% |
Analyst Consensus | Strong Buy |
Analyst Count | 18 |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | 2 |